Literature DB >> 1654436

Role of immune cells in protection against and control of reovirus infection in neonatal mice.

H W Virgin1, K L Tyler.   

Abstract

We studied the role of T cells in resistance to reovirus intestinal and central nervous system infection. Transfer of reovirus-immune adult spleen cells protected neonatal mice from (i) lethal infection with reovirus serotype 3 Dearing (T3D, footpad inoculation) and serotype 3 clone 9 (T3C9, oral inoculation) and (ii) hydrocephalus caused by serotype 1 Lang (T1L, intracranial [i.c.] inoculation). Cell-mediated protection was not serotype specific. While immune cells protected against T1L i.c., they failed to protect against 1/5,000 of the dose of T3D i.c. Two types of experiments showed that both CD4 and CD8 T cells are involved in reovirus resistance. First, immune cell-mediated protection against T3D was abrogated by in vivo treatment with anti-CD4 monoclonal antibody (MAb) and significantly inhibited by in vivo treatment with anti-CD8 MAb. Second, T3C9-infected neonatal mice treated with anti-CD4 and/or anti-CD8 developed a novel disease phenotype, an oily hair syndrome, associated with severe hepatobiliary pathology and increased viral titer in heart and liver. Immune cells and an MAb to the cell attachment protein sigma 1 (MAb G5) protected by different mechanisms. Immune cells were more effective than sigma 1 MAb G5 at controlling primary replication, while sigma 1 MAb G5 was more effective than immune cells at inhibiting neural spread of virus. We conclude that both CD4 and CD8 T cells are important for reovirus resistance, that cells and antibody act preferentially at different stages in pathogenesis in vivo, and that adoptively transferred immune cells can protect both the central nervous system and intestine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1654436      PMCID: PMC248992     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  MURINE INFECTION WITH REOVIRUS TYPE 3 AND THE RUNTING SYNDROME.

Authors:  N F STNALEY; P J LEAK
Journal:  Nature       Date:  1963-09-28       Impact factor: 49.962

2.  MURINE INFECTIONS WITH REOVIRUS. II. THE CHRONIC DISEASE FOLLOWING REOVIRUS TYPE 3 INFECTION.

Authors:  N F STANLEY; P J LEAK; M N WALTERS; R A JOSKE
Journal:  Br J Exp Pathol       Date:  1964-04

3.  Serologic grouping of reoviruses by hemagglutination-inhibition.

Authors:  L ROSEN
Journal:  Am J Hyg       Date:  1960-03

4.  Evidence for functional domains on the reovirus type 3 hemagglutinin.

Authors:  S J Burstin; D R Spriggs; B N Fields
Journal:  Virology       Date:  1982-02       Impact factor: 3.616

5.  Host immune response to reovirus: CTL recognize the major neutralization domain of the viral hemagglutinin.

Authors:  R Finberg; D R Spriggs; B N Fields
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

6.  Mucosal immune response to poliovirus vaccines in childhood.

Authors:  P L Ogra
Journal:  Rev Infect Dis       Date:  1984 May-Jun

7.  Age dependent susceptibility to Reovirus type 3 encephalitis: role of viral and host factors.

Authors:  M Tardieu; M L Powers; H L Weiner
Journal:  Ann Neurol       Date:  1983-06       Impact factor: 10.422

8.  Molecular basis of reovirus virulence. Role of the M2 gene.

Authors:  D H Rubin; B N Fields
Journal:  J Exp Med       Date:  1980-10-01       Impact factor: 14.307

9.  Antibody inhibits defined stages in the pathogenesis of reovirus serotype 3 infection of the central nervous system.

Authors:  K L Tyler; H W Virgin; R Bassel-Duby; B N Fields
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

10.  In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific.

Authors:  A E Lukacher; V L Braciale; T J Braciale
Journal:  J Exp Med       Date:  1984-09-01       Impact factor: 14.307

View more
  18 in total

1.  Macrophages are the major reservoir of latent murine gammaherpesvirus 68 in peritoneal cells.

Authors:  K E Weck; S S Kim; I V Virgin HW; S H Speck
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  IFN-gamma action in the media of the great elastic arteries, a novel immunoprivileged site.

Authors:  A J Dal Canto; P E Swanson; A K O'Guin; S H Speck; H W Virgin
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

3.  Reovirus mu1 structural rearrangements that mediate membrane penetration.

Authors:  Lan Zhang; Kartik Chandran; Max L Nibert; Stephen C Harrison
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

Review 4.  Natural pathogens of laboratory mice, rats, and rabbits and their effects on research.

Authors:  D G Baker
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

5.  Genetic mapping of reovirus virulence and organ tropism in severe combined immunodeficient mice: organ-specific virulence genes.

Authors:  B L Haller; M L Barkon; G P Vogler; H W Virgin
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

6.  Role of immunoglobulin A in protection against reovirus entry into Murine Peyer's patches.

Authors:  K J Silvey; A B Hutchings; M Vajdy; M M Petzke; M R Neutra
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Association of the reovirus S1 gene with serotype 3-induced biliary atresia in mice.

Authors:  G A Wilson; L A Morrison; B N Fields
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

8.  Lymphocytes protect against and are not required for reovirus-induced myocarditis.

Authors:  B Sherry; X Y Li; K L Tyler; J M Cullen; H W Virgin
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

9.  Reovirus replication protein μ2 influences cell tropism by promoting particle assembly within viral inclusions.

Authors:  Laura S Ooms; W Gray Jerome; Terence S Dermody; James D Chappell
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

10.  Circulating immunoglobulin G can play a critical role in clearance of intestinal reovirus infection.

Authors:  M L Barkon; B L Haller; H W Virgin
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.